In geroprotection, weekly pulsatile dosing (5–6 mg/week) has been explored to minimize adverse effects; ONLY under expert medical supervision.
A single 12 mg dose blocks the rise in post-exercise muscle protein synthesis; 20 mg/day suppresses all synthesis.
View the study (RCT) →First drug to extend the median lifespan of mice of both sexes (+22 to +48% in old females). Reduces mouse mortality mainly via cancer suppression.
View the study (preclinical) →10 weeks of rapamycin improved cardiac function in healthy older dogs; youthful functional restoration.
⏱ 4 min read
Rapamycin, also known in its pharmaceutical form as sirolimus, is a drug discovered in the 1970s from a soil bacterium on Easter Island (Rapa Nui), and it has since lived three parallel lives: that of the immunosuppressant that prevents rejection of organ transplants, that of the antitumor agent used in certain advanced cancers, and that of the experimental drug that longevity medicine is investigating in the hope of delaying human biological aging.
The molecular mechanism by which it works is what makes it a fascinating compound for longevity researchers: rapamycin selectively inhibits the mTORC1 complex, a cellular pathway that senses nutrients and energy and that, when constantly activated, accelerates cell growth and aging; by partially inhibiting it, the cell enters a conservation mode similar to the one activated by fasting and caloric restriction, two of the non-pharmacological interventions with the strongest geroprotective evidence.
In 2009, a study published in the journal Nature by the network of centers of the U.S. National Institute on Aging's Interventions Testing Program showed that rapamycin extended the median lifespan of mice of both sexes, with increases of 22 to 48 percent in old females, a landmark finding because it was the first time the lifespan of a mammal had been extended with a pharmacological compound approved for human use, opening the door to a conversation that until then belonged exclusively to basic science.
Later studies in dogs have continued to show intriguing results: ten weeks of rapamycin improved cardiac function in healthy older dogs, with structural and functional changes reminiscent of a younger heart, and the Dog Aging Project, currently under way, is trying to replicate these findings on a large scale in companion dogs from volunteer families, a smart methodological bridge between mouse biology and human biology.
Rapamycin has a dark side that anyone interested in using it should know about before any anti-aging promise: a single 12-milligram dose significantly blocks the rise in muscle protein synthesis that normally occurs after strength training, and daily doses of 20 milligrams suppress the muscle's entire anabolic response, which means that training hard while taking rapamycin can be literally counterproductive for maintaining muscle mass in older people.
This paradox explains why current experimental protocols in humans are exploring very low intermittent doses, on the order of 5 to 6 milligrams taken once a week, instead of the daily doses used in transplant recipients or in oncology: the idea is to trigger the geroprotective effect on mTORC1 without sustainedly blocking muscle protein synthesis, a strategy that requires fine-tuning and expert medical supervision, not something that can be done on your own with a product bought online.
The side effects of rapamycin are well documented from decades of clinical use in transplantation and cancer: stomatitis or oral ulcers, leukopenia with a drop in white blood cells, anemia, anorexia, fatigue, and lipid profile abnormalities that can raise cholesterol and triglycerides to a clinically significant degree, not to mention its immunosuppressive effect, which increases the risk of opportunistic infections, a concern that is especially relevant in older people whose immune system is already aged for other reasons.
Rapamycin should not be used outside carefully designed medical protocols, especially if the person is considering combining it with intense physical training or with other geroprotectors such as metformin, because the interactions between these compounds are not well characterized in humans and the effects on muscle health and quality of life may offset part of the theoretical benefit sought from the intervention itself.
Clinical trials of rapamycin in healthy humans are still small and exploratory: the PEARL trial, led by Matt Kaeberlein and published in 2024, evaluated intermittent dosing in healthy adults over 48 weeks and showed an acceptable safety profile along with some improvements in body composition and pain in women, but the effects on hard longevity markers such as mortality or the incidence of chronic diseases require much longer trials that have not yet been completed.
The honest conversation about rapamycin, therefore, is that of a drug with some of the strongest preclinical evidence in modern geroprotection but with a still-incipient translation to humans, and anyone considering using it should do so within the framework of rigorous medical supervision and, ideally, within a well-designed clinical trial that allows useful data to be accumulated for others.
Information, not medical advice. Scientific evidence reflects the quality of the studies.